Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to...

Полное описание

Библиографические подробности

Главные авторы:	Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O'Malley, Ursula Matulonis, Gottfried E. Konecny
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2023-06-01
Серии:	Gynecologic Oncology Reports
Предметы:	Ovarian cancer Antibody-drug conjugates Folate receptor alpha Mirvetuximab soravtansine Eye care Ocular adverse events
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2352578923000243
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!